<DOC>
	<DOCNO>NCT02474641</DOCNO>
	<brief_summary>Hypofractionation simultaneous integrate boost investigate trial appear safe feasible . Investigators initiate multicenter two-armed phase III prospective trial analyse non-inferiority hypofractionation simultaneous integrate boost patient early breast cancer comparison standard fractionation .</brief_summary>
	<brief_title>Hypofractionation With Simultaneous Integrated Boost vs. Standard Fractionation Early Breast Cancer</brief_title>
	<detailed_description>Control Arm : Conventionaly fractionate radiotherapy breast 28 × 1.8 Gy = 50.4 Gy follow tumor bed boost sequentially 5 8 × 2.0 Gy = 10.0 Gy 16.0 Gy , total dose 60.4 Gy 66.4 Gy . Conventionaly fractionate radiotherapy breast 28 × 1.8 Gy = 50.4 Gy simultaneous integrate boost tumor bed , total dose 28 × 0.3 Gy 0.45 Gy= 8.4 Gy 12,6 Gy , total dose 58,8 Gy 63.0 Gy . Hypofractionated radiotherapy breast 16 × 2.66 Gy = 42.56 Gy follow tumor bed boost sequentially 5 8 × 2.0 Gy = 10.0 Gy 16.0 Gy , total dose 52.56 Gy 58.56 Gy . Experimental Arm : Hypofractionated radiotherapy breast 16 × 2.50 Gy simultaneous integrate boost tumor bed , total dose within boost volume 16 × 3.00 Gy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histopathologically confirm breast cancer operate breast conserve surgery clear margin independently risk factor ( positive highrisk negative lymph node status , estrogen progesterone receptor status , Her2/neu status uPA/PAI1 criterion ) postoperative systemic therapy ( chemotherapy , endocrine , antibody bisphosphonate therapy permit indicate ) Indication adjuvant radiotherapy include boost radiotherapy Clearly identify primary tumor region preferably radiopaque clip Primary wind heal breast conserve therapy without sign infection Age ≥ 18 year ECOG ≤ 2 Performance Status Written inform consent Compliance regard treatment appointment toxicity Linguistic cognitive ability understand questionnaires Patients operate mastectomy No indication boost radiation ( e.g . status IORT ) double side breast cancer Resection margin positive disease insufficient identification boost volume Indication radiotherapy regional lymph node History prior breast thoracic radiotherapy Extended postoperative seroma begin radiotherapy Previously administer radiotherapy allow require dose Pregnant lactating patient woman child bear potential , lack effective contraception treatment history cancer participation another clinical trial test radiotherapy drug within 4 week start treatment . Patients serious , uncontrolled , physical cerebrovascular disorder ( e.g . myocardial infarction within last 12 month ) neurologiy psychiatric disorder think adversly affect treatment compliance</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Hypofractionation SIB</keyword>
	<keyword>Non-inferiority</keyword>
	<keyword>adjuvant radiotherapy simultaneous integrate boost</keyword>
</DOC>